Get started
Author

Erin H. Jensen

Observed names: E.H. Jensen, ERIN H. JENSEN, Erin H Jensen, Erin Jensen
Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Marshfield Clinic, University of California, Los Angeles, University of California, Irvine, CGH Medical Center, Miller Children's & Women's Hospital, Marshfield Clinic
ORCID: 0009-0006-1772-0225
Observed ORCID: 0009-0006-1772-0225
OpenAlex ID: A5111905731
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
2021 · Martin Reck, Delvys Rodríguez-Abreu, et al. · Journal of Clinical Oncology · 1,166
PDF
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
2023 · Marina C. Garassino, Shirish Gadgeel, et al. · Journal of Clinical Oncology · 729
PDF
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
2023 · Silvia Novello, Dariusz M. Kowalski, et al. · Journal of Clinical Oncology · 560
PDF
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
2021 · Roy S. Herbst, Edward B. Garon, et al. · Journal of Thoracic Oncology · 320
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
2020 · Roy S. Herbst, Edward B. Garon, et al. · Journal of Clinical Oncology · 282
PDF
Ertapenem versus Cefotetan Prophylaxis in Elective Colorectal Surgery
2006 · Kamal M.F. Itani, Samuel E. Wilson, et al. · New England Journal of Medicine · 276
PDF
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
2021 · Paul Nghiem, Shailender Bhatia, et al. · Journal for ImmunoTherapy of Cancer · 145
PDF
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
2019 · R.S. Herbst, P. Baas, et al. · Annals of Oncology · 105
PDF
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
2018 · Matteo S. Carlino, Georgina V. Long, et al. · European Journal of Cancer · 100
PDF
Effect of Body Mass Index and Ertapenem versus Cefotetan Prophylaxis on Surgical Site Infection in Elective Colorectal Surgery
2008 · Kamal M.F. Itani, Erin H. Jensen, et al. · Surgical Infections · 56
Randomized, Multicenter, Double-Blind Study of Efficacy, Safety, And Tolerability of Intravenous Ertapenem Versus Piperacillin/Tazobactam in Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults
2007 · Nicholas Namias, Joseph S. Solomkin, et al. · Surgical Infections · 51
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
2021 · Jean-François Timsit, Jennifer A. Huntington, et al. · Critical Care · 47
PDF
Kinetics of maternal hepatitis a antibody decay in infants: implications for vaccine use
2002 · Jay M. Lieberman, Swei-ju Chang, et al. · The Pediatric Infectious Disease Journal · 45
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up
2024 · Shirish M. Gadgeel, Delvys Rodríguez-Abreu, et al. · Journal of Thoracic Oncology · 44
PDF
5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.
2018 · Omid Hamid, Caroline Robert, et al. · Journal of Clinical Oncology · 40
Polyethylene glycol versus sodium phosphate mechanical bowel preparation in elective colorectal surgery
2007 · Kamal M.F. Itani, Samuel E. Wilson, et al. · The American Journal of Surgery · 36
Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.
2020 · Georgina V. Long, Jacob Schachter, et al. · Journal of Clinical Oncology · 33
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial
2021 · Brian I. Rini, Michael B. Atkins, et al. · European Urology Oncology · 32
Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial
2012 · John R. Guyton, Sergio Fazio, et al. · Diabetes Care · 27
Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 100-mg Regimen in Protease Inhibitor–Naive HIV-Infected Adults
2002 · Benjamin Young, Margaret A. Fischl, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 27
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia
2021 · Ignacio Martin-Loeches, Jean-François Timsit, et al. · Journal of Antimicrobial Chemotherapy · 25
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
2021 · Omid Hamid, Caroline Robert, et al. · European Journal of Cancer · 25
Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
2010 · Harold Bays, Scott Conard, et al. · Lipids in Health and Disease · 25
PDF
Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection
2018 · Thomas Birch, Yoav Golan, et al. · Journal of Antimicrobial Chemotherapy · 23
PDF
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial
2021 · Andrew F. Shorr, Christopher J. Bruno, et al. · Critical Care · 22
PDF
Works count: 77
Citation count: 4,513
H-index: 23
I10-index: 38
Year
Topic
Type